Buffett Brain · Research note
Score updated 26 Sept 2026 · analysis from 10 Jun 2026
LMAT· Healthcare
LeMaitre Vascular
LeMaitre Vascular's strong operating margins and solid revenue growth are offset by high valuation multiples and a below-average gross margin.
Buffett fit
Strong fit
Owner
57
Durability
82
Management
81
Price
9
Score updated 26 Sept 2026 · analysis from 10 Jun 2026
Buffett's checklist
Each number against Buffett's bar, and where it ranks among Healthcare stocks in our database.
How much profit the business makes on each dollar invested in it. Higher is better.
What is left of each sale after the cost of making the product. A high number often means pricing power.
The cash the business earns for its owners, compared with the price of the whole company.
How fast sales grew each year over the last five years.
How many years of today's profit you pay for at today's price. Lower means cheaper.
How much the company owes compared with what it owns outright. Lower is safer.
The four pillars
How the business measures up on each of Buffett's four tests.
If I owned 100% of LeMaitre, I'd focus on expanding their product offerings and market presence, leveraging their 12.75% revenue CAGR.
The full reasoning comes with a free account.
LeMaitre has shown durability with consistent profitability over the last five years, but the risk of technological disruption or regulatory changes could impact their competitive position.
The full reasoning comes with a free account.
Management has maintained a flat share count with a 1.71% CAGR over five years, which is a positive sign.
The full reasoning comes with a free account.
Current valuation metrics are concerning, with a of 37.1 and an yield of only 3.21%.
The full reasoning comes with a free account.
Free account
Read the full LeMaitre Vascular analysis free
- The full reasoning behind all four pillars
- Graham, Lynch and Greenblatt on the same stock
3 full analyses a week · no card needed
For and against
The strongest points on each side, with the numbers behind them.
In its favor
5- 1 of 28.5% ranks in the top quintile for the healthcare sector.
- 2Consistent revenue growth with a 5-year CAGR of 12.75%.
- 3 growth of 100.39% year-over-year indicates strong cash generation.
- 4Net margin of 24.3% is well above the sector's top-quintile cutoff.
Concerns
5- 1 of 72.4% is below the sector's top-quintile cutoff of 78.4%.
- 2 of 37.1 suggests the stock is overvalued relative to earnings.
- 3 yield of 3.21% is significantly below the desired 8-10%.
- 4No over the last five years raises questions about .
Price history
$82.87+59.3%· 5-year return
Weekly closing prices. Touch or hover the line for a date.
The business
How the business works
LeMaitre Vascular generates cash through a variety of medical devices for peripheral vascular disease, with a TTM revenue of $249.6M. Their products, including catheters and grafts, are marketed through a direct sales force and distributors. The high of 72.4% indicates strong and efficient operations.
What other investors would say
The same company, judged by three other documented playbooks.
Keep researching
Similar companies in Healthcare
Free weekly email
Liked the read on LMAT? Get the next ones on Monday.
Every Monday: the stocks most of the seven investors newly agree on. One email, unsubscribe any time.
Research, not investment advice.
See the Buffett analysis of LeMaitre Vascular
The score, the checklist and the full reasoning open with a free account. You get 3 full analyses a week, and this stock is the first one. No card needed.
Create a free account3 full analyses a week · no card needed
Already have an account? Sign in